Katharina Schubert

Katharina Schubert

Auto-generated profile, based on publicly available information

Katharina Schubert

Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2020 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
KSKatharina Schubert
Katharina Schubert
EKEvangelos D. Karousis
Evangelos D. Karousis
AJAhmad Jomaa
Ahmad Jomaa
ASAlain Scaiola
Alain Scaiola
BEBlanca Echeverria
Blanca Echeverria
NBNenad Ban
Nenad Ban

1 June 2021 in Molecular Cell
Verified
Journal Article
Closed access
EKEva Kummer
Eva Kummer
KSKatharina Noel Schubert
Katharina Noel Schubert
TSTanja Schoenhut
Tanja Schoenhut
ASAlain Scaiola
Alain Scaiola
NBNenad Ban
Nenad Ban

20 October 2020 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
KSKatharina Schubert
Katharina Schubert
EKEvangelos D. Karousis
Evangelos D. Karousis
AJAhmad Jomaa
Ahmad Jomaa
ASAlain Scaiola
Alain Scaiola
BEBlanca Echeverria
Blanca Echeverria
NBNenad Ban
Nenad Ban

10 January 2024 in The EMBO Journal
Verified
Journal Article
Open access
EKEvangelos D Karousis
Evangelos D Karousis
KSKatharina Schubert
Katharina Schubert
NBNenad Ban
Nenad Ban
Coronaviruses are a group of related RNA viruses that cause respiratory diseases in humans and animals. Understanding the mechanisms of translation regulation during coronaviral infections is critical for developing antiviral therapies and preventing viral spread. Translation of the viral single-stranded RNA genome in the host cell cytoplasm is an essential step in the life cycle of coronaviruses, which affects the cellular mRNA translation landscape in many ways. Here we discuss various viral strategies of translation control, including how members of the Betacoronavirus genus shut down host cell translation and suppress host innate immune functions, as well as the role of the viral non-structural protein 1 (Nsp1) in the process. We also outline the fate of viral RNA, considering stress response mechanisms triggered in infected cells, and describe how unique viral RNA features contribute to programmed ribosomal −1 frameshifting, RNA editing, and translation shutdown evasion.

7 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKatharina Schubert
Katharina Schubert
EKEvangelos D. Karousis
Evangelos D. Karousis
AJAhmad Jomaa
Ahmad Jomaa
ASAlain Scaiola
Alain Scaiola
BEBlanca Echeverria
Blanca Echeverria
NBNenad Ban
Nenad Ban
The non-structural protein 1 (Nsp1), also referred to as the host shutoff factor, is the first viral protein that is synthesized in SARS-CoV-2 infected human cells to suppress host innate immune functions 1,2 . By combining cryo-electron microscopy and biochemical experiments, we show that SARS-CoV-2 Nsp1 binds to the human 40S subunit in ribosomal complexes including the 43S pre-initiation complex. The protein inserts its C-terminal domain at the entrance to the mRNA channel where it interferes with mRNA binding. We observe potent translation inhibition in the presence of Nsp1 in lysates from human cells. Based on the high-resolution structure of the 40S-Nsp1 complex, we identify residues of Nsp1 crucial for mediating translation inhibition. We further show that the full-length 5’ untranslated region of the genomic viral mRNA stimulates translation in vitro , suggesting that SARS-CoV-2 combines inhibition of translation by Nsp1 with efficient translation of the viral mRNA to achieve expression of viral genes 3 .

1 January 2020
Verified
Book Chapter
Open access
PDF file
JSJannik Schaaf
Jannik Schaaf
MSMartin Sedlmayr
Martin Sedlmayr
HPHans-Ulrich Prokosch
Hans-Ulrich Prokosch
TGThomas Ganslandt
Thomas Ganslandt
SCSchade-Brittinger Carmen
Schade-Brittinger Carmen
SHStorf Holger
Storf Holger
Clinical decision support systems (CDSS) help to improve the diagnostics and treatment of rare diseases (RD). As one of four funded consortia of the Medical Informatics Initiative supported by the Federal Ministry of Education and Research (BMBF, Germany), MIRACUM develops a clinical decision support system (CDSS) for RD based on distributed data of ten university hospitals. The CDSS will be developed at the Rare Diseases Centres (RDC) of the MIRACUM consortium. Since it is essential to deliver decision support at the right time and place in the clinician's workflow, this study aimed to capture relevant information of the RDCs regarding patient admission and diagnostic process. Additionally, we investigated how patient documentation and digitalisation is performed at the centres. Therefore, we conducted a cross-sectional survey involving experts in the RDs domain to capture relevant information for the further development of a CDSS in RD. For each centre, one expert on RDs participated in the study (n=8). The survey identified several challenges regarding the reuse of patient data, e.g. the paper-based documentation of a patientâĂŹs medical history and coding of diagnoses using ICD-10. However, we noticed a relevant use of current software diagnosis support and a similarly performed diagnostic process in all RDC. Further studies are needed to get more detailed insights and to define specific requirements.